福蒙尼丁可以通过改善线粒体功能障碍来改善异二醇诱导的心脏纤维化
Lei Qian1, Hu Xu2, Ruqiang Yuan3
1Department of Biochemistry and Molecular Biology, College of Basic Sciences, Dalian Medical University, Dalian 116044, China; Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|December 9, 2023
概括
甲米诺尼丁通过改善线粒体功能和减少心脏硬性,有效治疗心脏纤维化. 这种异黄针对心肌细胞中的ALDH2,HADH和MAOB,为心血管保护提供了一种新的治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 一种异黄的形式诺尼丁 (Formononetin) 具有已知的心血管保护作用.
- 福莫诺尼丁对心脏纤维化的影响仍然未被探索.
- 心脏纤维化是导致心脏病进展的重要因素.
研究的目的:
- 在小鼠中研究蒙尼丁在治疗异二醇诱导的心脏纤维化中的疗效.
- 阐明福莫诺尼丁心脏保护作用背后的分子机制,重点关注线粒体功能和特定的基因标.
主要方法:
- 建立心脏纤维化小鼠模型,使用异二醇 (ISO) 给药.
- 在接受治疗的小鼠中,通过口服给药福莫诺尼丁.
- 评估心脏功能 (E/A比率),纤维化 (马森染色),蛋白质和基因表达 (西方斑点,qPCR),代谢学和网络药理学.
- 在心肌细胞中验证关键标 (ALDH2,HADH,MAOB),包括线粒体膜潜力和ROS产生.
主要成果:
- 甲诺丁显著逆转了ISO诱导的心脏硬和抑制心脏纤维化标志物.
- 与纤维化相关的关键蛋白质和基因 (原III,纤维素,TGF-β1,α-SMA,维丁,Col1a1,Col3a1,Acta2,Tgfb1) 被蒙尼丁下调.
- 福莫诺丁通过调节心肌细胞中的ALDH2,HADH和MAOB表达来改善ISO诱导的线粒体功能障碍,改善线粒体膜潜力并减少ROS的产生.
结论:
- 福蒙诺丁在缓解心脏纤维化方面表现出显著的有效性.
- 心脏保护机制涉及心肌细胞中ALDH2,HADH和MAOB的调节,从而改善线粒体功能.
- 福蒙诺丁是治疗心脏纤维化和相关心血管疾病的有前途的治疗药物.
更多相关视频
10:21Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.1K
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
11.7K
相关概念视频
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
